GU Ventures
VC Fund
Gothenburg, Sweden
GU Ventures is a VC fund in Gothenburg focused on Pharmaceutical and Medical. Since 1995, GU Ventures has supported projects and companies spawned by the University of Gothenburg. The company is wholly owned by the Swedish state and managed since 1998 by the University of Gothenburg.They are located at Erik Dahlbergsgatan at Vasaplatsen in Gothenburg on the same street as the University of Gothenburg Research andInnovation Office, Företagarna and Nyföretagarcentrumand, within walking distance to the University of Gothenburg's main building and several faculties.In close collaboration with the Research and Innovation Office at GU, Innovationskontor Väst and the Gothenburg innovation system with partners such as Encubator, Chalmers Innovation, Framtidens Företag and Sahlgrenska Science Park, they contribute to the renewal of industry through commercialization of research and expertise.All business ideas must have commercial viability and solve a problem for a customer. The companies shall strive to become profitable and successful by satisfying a market need.The aim is to create successful businesses to generate good knowledge- and capital repayment to the University of Gothenburg. Furthermore, they intend to increase growth in the region and contribute to the utilization of research for a better life and society with new products and services.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries GU Ventures invests in
Stages GU Ventures invests in
Countries GU Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $1M–$2.9M
- Series A
- $2.3M–$73M
- Venture - Series Unknown
- $794k–$1.5M
Investment Focus
Industry
- Pharmaceutical 3 (33%)
- Medical 2 (22%)
- Health Care 2 (22%)
- Biotechnology 2 (22%)
- Eyewear 1 (11%)
Stage
- Seed 3 (33%)
- Series A 2 (22%)
- Venture - Series Unknown 2 (22%)
- Pre-Seed 1 (11%)
- Funding Round 1 (11%)
Country
- Sweden 6 (67%)
- United States 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Albertsson
Head of Strategic Projects and Deal-flow
|
Head of Strategic Projects and Deal-flow | Total investments: 0 | Find email | |
Håkan Sterner
CFO and vice CEO
|
CFO and vice CEO | Total investments: 0 | Find email | |
| CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NSS Water
|
NSS Water specializes in innovative water purification technology for high-tech sectors such as semiconductors. | $793.6K / Venture - Series Unknown / Feb 19, 2026 | |
Thioredoxin Systems
|
Thioredoxin Systems develops innovative antibiotic regimen for complicated urinary tract infections. | $2.3M / Series A / Oct 30, 2024 | |
Mimbly
|
Mimbly saves water(s) by creating innovative solutions for water saving and microplastic capturing. | $1.5M / Venture - Series Unknown / Jul 01, 2024 | |
|
Navari
|
Navari is a software technology company that develops a navigation system for minimally invasive surgery. Their objective is to make minimally invasive cancer surgery available to everyone, making it the preferred technique over open surgery. To do this, they created a software system that provides intraoperative guidance during minimally invasivesurgeries, resulting in improved visibility and more precise tumor removal.Navari is headquartered in Gothenburg, Sweden and was founded in 2021. | $716.7K / Pre-Seed / Nov 15, 2022 | |
Pretzel Therapeutics
|
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinatingfeatures that make it unlike any other organelle in the body. | $72.5M / Series A / Sep 12, 2022 | |
Profundus Imaging
|
Profundus Imaging is developed a new fundus camera that could be used to provide researchers and clinicians with a tool that can visualize currently subclinical changes of retinal disease. The camera is built on so-called Adaptive Optics, a technology that is normally used in terrestrial space telescopes and was developed due to a need for improvedresolution in retinal imaging and offers 7-10 times higher resolution than conventional instruments over a considerably larger imaging area than competing concepts. | $1M / Seed / Jan 19, 2021 | |
OnDosis
|
OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development. | $3.4M / Seed / Sep 11, 2020 | |
|
Mimbly
|
Mimbly saves water(s) by creating innovative solutions for water saving and microplastic capturing. | $820K / Jan 17, 2020 | |
Cereno Scientific AB
|
Cereno Scientific AB develops a new innovative treatment for patients with increased risk of blood clotting, based on the company's newly patented research findings. Cereno Scientific AB develops drugs that normalize the body's own defense system against blood clots for the treatment of complications in cardiovascular diseases. | Seed / Apr 01, 2012 |
Co-Investors
Almi Invest
3 deals together
ARCH Venture Partners
3 deals together
Forec
2 deals together
GOBIA Enterprises
2 deals together
Google Ventures
2 deals together
Mubadala Capital Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does GU Ventures invest in?
GU Ventures invests primarily in Pharmaceutical, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is GU Ventures's check size?
GU Ventures typically joins rounds of $1M–$2.9M at Seed, $2.3M–$73M at Series A and $794k–$1.5M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds GU Ventures participates in.
How do I contact GU Ventures?
Public channels for GU Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GU Ventures?
The team at GU Ventures includes Andreas Albertsson (Head of Strategic Projects and Deal-flow), Håkan Sterner (CFO and vice CEO) and Klementina Österberg (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
